Time Bio Management

The named principals and investment team at Time Bio Management are not publicly disclosed in any regulatory filings, press releases, or company databases. No information is available about the CEO, CIO, or managing partners who make investment decisions for the firm.

The firm likely sources investment opportunities through relationships with biotechnology industry executives, academic research institutions, and venture capital firms focused on life sciences. Without public filings or a company website, the specific sourcing model remains unverified.

The firm is organized as a limited liability company, which could serve either as a single-family office, a multi-family office, or an asset manager with a biotech focus. The absence of public disclosures about beneficiaries or external investors makes the specific structure unclear.

No public records indicate whether Time Bio Management invests through fund commitments, direct investments, co-investments, or special purpose vehicles. Biotech-focused family offices often use a mix of venture fund allocations and direct positions in private companies.

The likely stage focus for a biotech investment firm includes early-stage drug development, clinical-stage companies, and growth-stage healthcare services firms. No confirmed portfolio companies or deal history exists in public sources to verify the typical investment stage.